 "Lupin Pharma")
Lupin's performance in December quarter was ahead of Street estimates. Buoyed by growth across geographies, sales grew 32 per cent to Rs 4,405 crore over a year ago, ahead of Bloomberg consensus estimate of Rs 4,293 crore. Operating or underlying profit was even more impressive at Rs 1,215.8 crore, up 43.6 per cent year over year, and way ahead of Rs 1,061.4-crore estimate. The operating margin at 27.6 per cent grew 230 basis points year over year. Despite higher taxes, net profit saw 20.7 per cent growth to Rs 619 crore.
Profit growth was largely a function of its performance in
